Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

McMaster University

$90,000.00

Elucidating the role of host and bacterial proteolytic activity in inflammatory bowel disease

FY 2023-24

Summary
Inflammatory Bowel Diseases (IBD) are lifelong debilitating conditions of the gut that are becoming more frequent in Canada. The causes are unknown, but we know environmental factors such as gut microbes are driving this increase, although it is unclear how they do it. "Proteases" are molecules that are produced by our body to breakdown the proteins we ingest with food, immune cells during inflammation, and gut bacteria that use this activity to extract energy for themselves. If proteases are overactive, particularly from bacteria, this activity can damage our tissues. We have shown that patients at risk for IBD have overactive bacterial proteases before the onset of ulcerative colitis (UC), one form of IBD. We have recently shown that patients with Crohn's disease, the other form of IBD, have overactive proteases in feces as well. However, it is unclear if this overactivity comes from immune cells or gut bacteria, or both. This is important to elucidate, if we are to target this activity selectively as a new therapy for IBD. My project will determine whether the overactive proteases seen in patients with IBD originate first from immune cells invading the gut or from the gut bacteria harboured by these patients. Once determined, I will test a newly developed probiotic designed specifically to inhibit proteases. This probiotic is unique in that it cannot survive outside of the human gut, preventing spread of the probiotic into the environment. I will use samples from IBD patients and microbial methods available in my supervisor's lab and exploit my expertise in immunology. With Canada having one of the highest rates of IBD in the world, it is important we better understand what is driving this increase. Our results will enhance the knowledge regarding the origin of proteases in IBD and test a novel therapeutic option, which can be applied in the future in a personalized manner to IBD patients with protease overactivity.
Program
CIHR Fellowship
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
492714
Name
Bording-Jorgensen Michael W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Elucidating the role of host and bacterial proteolytic activity in inflammatory bowel disease
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Immunology; Inflammatory Bowel Diseases; Microbiology; Microbiome
Abstract
Inflammatory Bowel Diseases (IBD) are lifelong debilitating conditions of the gut that are becoming more frequent in Canada. The causes are unknown, but we know environmental factors such as gut microbes are driving this increase, although it is unclear how they do it. "Proteases" are molecules that are produced by our body to breakdown the proteins we ingest with food, immune cells during inflammation, and gut bacteria that use this activity to extract energy for themselves. If proteases are overactive, particularly from bacteria, this activity can damage our tissues. We have shown that patients at risk for IBD have overactive bacterial proteases before the onset of ulcerative colitis (UC), one form of IBD. We have recently shown that patients with Crohn's disease, the other form of IBD, have overactive proteases in feces as well. However, it is unclear if this overactivity comes from immune cells or gut bacteria, or both. This is important to elucidate, if we are to target this activity selectively as a new therapy for IBD. My project will determine whether the overactive proteases seen in patients with IBD originate first from immune cells invading the gut or from the gut bacteria harboured by these patients. Once determined, I will test a newly developed probiotic designed specifically to inhibit proteases. This probiotic is unique in that it cannot survive outside of the human gut, preventing spread of the probiotic into the environment. I will use samples from IBD patients and microbial methods available in my supervisor's lab and exploit my expertise in immunology. With Canada having one of the highest rates of IBD in the world, it is important we better understand what is driving this increase. Our results will enhance the knowledge regarding the origin of proteases in IBD and test a novel therapeutic option, which can be applied in the future in a personalized manner to IBD patients with protease overactivity.
Competitiondate
202310
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Bording-Jorgensen, Michael W
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~
McMaster University - $90,000 Grant (2023-24) | Canada Spends